Disrupting the FDA: industry insiders offer up a wish list and highlight challenges

How to prove innovation, shaking up clinical trial designs and figuring out the right balance between too much regulation and not enough. Those were some of the issues discussed at Forbes inaugural healthcare conference in New York this week.